Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin.

[anacleta]

Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin

Article type: Research Article

Authors: Healy, Davida; | Bahrick, Audreyb | Bak, Maartenc; d | Barbato, Angeloe | Calabrò, Rocco Salvatoref | Chubak, Barbara M.g | Cosci, Fiammettac; h; i | Csoka, Antonei B.j | D’Avanzo, Barbarae | Diviccaro, Silviak | Giatti, Silviak | Goldstein, Irwinl; m | Graf, Heikon | Hellstrom, Wayne J.G.o | Irwig, Michael S.p; q | Jannini, Emmanuele A.r | Janssen, Paddy K.C.s; t | Khera, Mohitu | Kumar, Manoj Therayilv | Le Noury, Joannaw | Lew-Starowicz, Michałx | Linden, David E.J.y | Lüning, Celinez | Mangin, Deea | Melcangi, Roberto Cosimok | Rodríguez, Omar Walid Muquebil Ali Al Shabanaa | Panicker, Jalesh N.ab; ac | Patacchini, Ariannah | Pearlman, Amy M.ad | Pukall, Caroline F.ae | Raj, Sanjanaaf | Reisman, Yacovag | Rubin, Rachel S.ah | Schreiber, Rudyai | Shipko, Stuartaj | Vašečková, Barboraak | Waraich, Ahadm

Affiliations: [a] Department of Family Medicine, McMaster University, Hamilton, ON, Canada | [b. ] University Counseling Service, University of Iowa, Iowa City, IA, USA | [c] Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands | [d] FACT, Mondriaan Mental Health, Maastricht/Heerlen, The Netherlands | [e] Unit for Quality of Care and Rights Promotion in Mental Health, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy | [f] IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy | [g] Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA | [h] Department of Health Sciences, University of Florence, Florence, Italy | [i. ] Clinical Pharmacopsychology Laboratory, University of Florence, Florence, Italy | [j] Department of Anatomy, Howard University College of Medicine, Washington, DC, USA | [k] Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy | [l] Alvarado Hospital, San Diego, CA, USA | [m] San Diego Sexual Medicine, San Diego, CA, USA | [n] Department of Psychiatry and Psychotherapy, Ulm University, Ulm, Germany | [o] Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA | [p] Beth Israel Deaconess Medical Center, Boston, MA, USA | [q] Harvard Medical School, Boston, MA, USA | [r] Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy | [s] Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands | [t] Department of Hospital Pharmacy, VieCuri Medical Center, Venlo, The Netherlands | [u. ] Department of Urology, Baylor School of Medicine, Houston, TX, USA | [v] Institute for Mind and Brain, Kerala, India | [w] North Wales Department of Psychological Medicine, Bangor, Wales, UK | [x] Department of Psychiatry, Centre of Postgraduate Medical Education, Warsaw, Poland | [y] School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands | [z] Department of Psychology and Psychotherapy, Witten/Herdecke University, Germany | [aa] Psychiatry Service, Hospital Universitario San Agustín, Avilés, Asturias, Spain | [ab] Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK | [ac] Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK | [ad] Carver College of Medicine, University of Iowa Health Care, Iowa City, IA, USA | [ae] Department of Psychology, Queen’s University, Kingston, ON, Canada | [af] Faculty of Social and Behavioural Sciences, Utrecht University, Utrecht, The Netherlands | [ag] Flare-Health, Amstelveen, The Netherlands | [ah] Department of Urology, Georgetown University School of Medicine, Washington, DC, USA | [ai] Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands | [aj] Private Practice, Pasadena, CA, USA | [ak] Psychiatric Clinic, Slovak Medical University and University Hospital, Bratislava, Slovakia

Correspondence: [*] Address for correspondence: David Healy, Department of Family Medicine, McMaster University, David Braley Health Sciences Centre, 100 Main Street West, 5th Floor, Hamilton, ON L8P 1H6, Canada. Tel.: +1 365 336 9817; E-mail: david.healy54@gmail.com

Abstract: BACKGROUND: A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin. OBJECTIVE: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD). METHODS: The original draft was designed using data from two published case series (Hogan et al., 2014 and Healy et al., 2018), which represent the largest public collections of data on these enduring conditions. It was further developed with the involvement of a multidisciplinary panel of experts. RESULTS: A set of criteria were agreed upon for each of the above conditions. Features of PSSD, PFS and PRSD commonly include decreased genital and orgasmic sensation, decreased sexual desire and erectile dysfunction. Ancillary non-sexual symptoms vary depending on the specific condition but can include emotional blunting and cognitive impairment. PGAD presents with an almost mirror image of unwanted sensations of genital arousal or irritability in the absence of sexual desire. A new term, post-SSRI asexuality, is introduced to describe a dampening of sexual interest and pleasure resulting from a pre-natal or pre-teen exposure to a serotonin reuptake inhibitor. CONCLUSIONS: These criteria will help in both clinical and research settings. As with all criteria, they will likely need modification in the light of developments.

Keywords: Post-SSRI sexual dysfunction, antidepressants, selective serotonin reuptake inhibitors, finasteride, isotretinoin

DOI: 10.3233/JRS-210023

Journal: International Journal of Risk & Safety in Medicine, vol. Pre-press, no. Pre-press, pp. 1-12, 2021

Received 30 April 2021 | Accepted 07 October 2021 | Published: 26 October 2021

https://www.researchgate.net/publicatio ... otretinoin

[anacleta]

note the remarkable collaboration of authors from several countries! great, I hope this one will have more impact

[nicopickle]

i feel like this study is the perfect thing for new studies to go off. these 3 drugs all have something in common on how they destroy peoples lives. i don’t see why more studies aren’t looking into the similarities between these 3 drugs. finding similarities would cause a conclusion so much quicker.

[sylv]

First and foremost these 3 drugs have one thing in common - faulty pharmacoviligance and clinical trials which missed them. The problem itself is more wider, add Fluoroquinolones and FQAD, Statins, Birth pills, Antipsychotics and Tetracyclines.

The medicine is not safe anymore. All these conditions should associate in one Post Drug Syndrome Foundation and do activism, find the guilty together.

[nicopickle]

First and foremost these 3 drugs have one thing in common - faulty pharmacoviligance and clinical trials which missed them. The problem itself is more wider, add Fluoroquinolones and FQAD, Statins, Birth pills, Antipsychotics and Tetracyclines.

The medicine is not safe anymore. All these conditions should associate in one Post Drug Syndrome Foundation and do activism, find the guilty together.

I 100% agree with you. all of these drugs must be doing something similar. I wish there was a combined drug group made for everyone suffering from these symptoms. It would not only bring in more attention to this horrible condition, but would also allow more research done through combined funding. I like what the pfs group is doing, however I think they are really missing opportunities going on just pfs. even though its very likely that we all suffer from the exact same condition triggered by these drugs.